Clinical Trial Update: A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel [Phase 2]

View source ↗

Summary

Phase 2 biomarker study in HER2-negative metastatic breast cancer treated with bevacizumab and paclitaxel has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Theodoros Foukakis | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED